Eu MDR
Eu MDR
Eu MDR
directive vs regulation
Geert Corstens
1 November 2018
Agenda
Current Medical Device regulatory landscape
New Medical Device Regulation EU
Interaction & impact Medical device with pharma
2
Current Medical Device regulatory
landscape
any instrument, apparatus, appliance, software, implant, reagent, material or other article intended
by the manufacturer to be used, alone or in combination, for human beings for
one or more of the following specific medical purposes:
• diagnosis, prevention, monitoring, prediction, prognosis,
treatment or alleviation of disease,
• diagnosis, monitoring, treatment, alleviation of, or compensation for, an injury or disability,
• investigation, replacement or modification of the anatomy or of a physiological or pathological process or state,
• providing information by means of in vitro examination of specimens derived from the human body, including
organ, blood and tissue donations,
3
Examples medical devices
4
How to market
Development QMS
CE
EU
mark Market
Manufacturing
5
Current Medical Device
Directive (MDD)
Enforced 1993, last update 2010.
Product classification I, IIa, IIb, III
Market authorization routes
Notified body
Economic operators
Risk management
6
Current Medical Device
Directive (MDD)
Performance
Safety
Labeling
QMS/manufacturing/development
Post market surveillance
7
Technical documentation
• Essential requirements (Annex I)
• Risk Management File
• Clinical evaluation
• Biological safety evaluation
• Control of manufacturing
• Stability
• Quality management system
• Performance testing
• Used guidelines
8
Guidance documents
• MEDDEV
Classifications of Medical Devices
Clinical Investigation, clinical evaluation
Notified Bodies
Market Surveillance (vigilance reporting, PMCF studies,..)
• ISO standards
• NB-MED
• IMDRF (harmonization)
9
Shortcommings MDD
Borderline products classification
Clinical requirements (equivalence vs clinical trials)
Notified body competence
Economic operator responsibilities
Post market requirements
Medical device traceablity
10
Incentive new regulation
11
PIP implant
Fraudulent use of non-medical grade silicone in breast implants by
company PIP (Poly Implant Prothèse) in France
1997: PIP is authorized to produce implants made of medical
silicone
2001: PIP starts using industrial silicone in their in-house
produced implants, with:
• Cost savings of around 90%
• 500% higher risk of rupturing or leaking
Between 2001 and 2010: reports of several incidents
(death/breast cancer)
~300.000 women affected in 65 countries
12
Actions
PIP action plan (2012)
• Tighten controls
• Guarantee safety
• Restore patient confidence in law
13
MDR 2017/745
Regulation vs Directive
175 page document vs 60 MDD
123 articles and 16 Annexes vs 23 articles and 12 Annexes
MDD and AIMDD integrated
MEDDEV guidelines integrated
Shift from pre-approval stage to ‘life-cycle approach’
More EU control
More NB harmonization
Active 26 may 2020
New MDR CE certificates for existing devices.
14
Key changes in the MDR
New product General safety
Clinical
types and Notified bodies and performance
requirements
classification rules requirements
Increase
Equivalency
Software designation Risk/benefit
limitations
requirements
Harmonization
Substance based PMCF
of quality NB’s QMS
medical devices requirements
(e.g. joint audits)
Annual update
Non-vital
safety & UDI
human tissue performance
Cosmetic
Labeling
devices
Toxic
substances
15
Key changes in the MDR
Central
Technical
Responsible registration
documentation MDCG
person for RA economic
requirements
operators
Common
Eudamed UDI Expert panels
specifications
16
timelines
17
MDR interaction with pharma
18
MDR interaction with pharma
19
MDR interaction with pharma
20
‘combination’ product
‘Combination’ options
• Single integral products
• the device and the medicinal product form a
single integral product;
• intended exclusively for use in the given
combination;
• not reusable
• Co-pack
• MP and MD are packed together and intended
to be used together
21
Current role EMA
~13% of MAA contain device
Single integral:
• EMA assesses compliance with MDD requirements
• Labeling/instruction for use
• PMS for device
• Authorise changes to device
CE marketed devices:
• Check validity CE certificate
• Evaluate compatibiliy with medicinal product.
22
What is the impact of MDR on
pharma
Classification
Art 117
Notified body interaction
• CE certificate from NB
• NB opinions
Device changes
New CE certificate
23
Classification
24
Article 117 (medical device as part of
medicinal product)
25
Device change
Device QMS
General safety &
performance requirements
NB approval/Opinion
26
Impact on medicinal product dossier
CTD module?
Requirements opinion art 117 by NB?
Labeling requirements?
UDI for device?
Variations?
Device specific post market requirements?
27
28
Uncertainties
EBE paper
• Art 117 opinion content
• NB assessment and opinion in parallel with MAA
• Opinion not required in development
• Class I devices no opinion required
• One opinion for a group of devices
• Device information in section 3.2.P.2.4
(container closure)
• No full labeling requirements MDR
29
Variations proposed on EBE paper
Change Justification Variation strategy
Prefilled syringe with fixed B.II.e.4 Change in shape or Type IB variation
needle and the dimensions dimension of the container or B.II.e.4.z
change closure
Changes or additional Conditions: No change to Non-reportable change
vendors for device registered detail. No
component anticipated impact of product
quality, safety or efficacy.
Change of supplier of the Assessed to be ‘non- Non-reportable change
needle for PFS reportable’ under EU
variation categories
Change in the assembly If the assembly operation is Type IA change under
process of the device reported within the dossier category B.II.b.1.a
EBE Reflection Paper Medicinal product incorporating a drug delivery device component: An Industry Perspective on the EU marketing
application technical requirements, regulatory review process and post-approval device related change assessment. 15 January 2018
30
Open issues for devices in medicinal
product
UDI requirements
EUDAMED obligations
Review time NB
Device specific post market requirements
Contractual agreements
31
How to comply with MDR
32
Take home message
33
34